116 compounds · evidence graded A to F · prices per mg from in-stock offers
peptide and research product database
Search 116 research product identities by name, alias, market and form. Read source-reviewed notes and compare dated vendor packages.
research market · not for human use
These vendors sell compounds as research chemicals. Most are not FDA-approved.
| compound | evidence | US status | from | lowest $/mg | median $/mg | vendors | assays per lot |
|---|---|---|---|---|---|---|---|
| Tirzepatide GIP/GLP-1 dual agonist | FDA-approved | $149.99 | $3.50 | $6.08 | 3 | 10× | |
| Semaglutide GLP-1 agonist | FDA-approved | $79.99 | $6.00 | $8.50 | 3 | 10× | |
| Tesamorelin GHRH analogue | FDA-approved | $74.99 | $7.50 | $9.00 | 4 | 9× | |
| PT-141 bremelanotide | FDA-approved | $39.99 | $4.00 | $6.00 | 5 | 9× | |
| Oxytocin neuropeptide hormone | FDA-approved | $35.00 | $5.00 | $9.00 | 4 | 6× | |
| Liraglutide GLP-1 agonist | FDA-approved | $51.00 | $10.20 | $10.20 | 1 | 4× |
6 of 116 compounds. Prices are listed prices before codes and shipping; per mg uses the package’s labelled amount. Evidence grades describe published human evidence, not product quality.
how the grades work
evidence grades
- approved, strong human outcome data
- phase 2–3 human trials, not yet approved
- small or early human studies
- animal or cell studies only
- contradicted, unsafe, or identity problems
Graded on published human evidence by an editorial first pass that is awaiting expert review. Grades come from the literature; no vendor can pay for a grade or a ranking. editorial policy